Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 25, 2017
Pharmacy Choice - News - Generic Drugs - February 25, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 153     Next >>     Go To Page:

2/18/17 - Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices - Research and Markets
By a News Reporter-Staff News Editor at Investment Weekly News Research and Markets has announced the addition of the "Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices" report to their offering. A biosimilars boom is expected and both biopharma and contract manufacturers want to be positioned to capture a piece of
2/18/17 - How States Are Using The Law To Bring Drug Executives To Heel [Above The Law]
The generic drug industry has come under fire the last couple of years because of staggering price increases.
2/18/17 - Investigators at Careggi University Hospital Describe Findings in Inflammatory Bowel Disease (Biosimilars in inflammatory bowel disease: A review of...
By a News Reporter-Staff News Editor at Marketing Weekly News Current study results on Digestive System Diseases and Conditions- Inflammatory Bowel Disease have been published. For more information on this research see: Biosimilars in inflammatory bowel disease: A review of post-marketing experience. World Journal of Gastroenterology, 2017; 23: 1
2/18/17 - New Psoriasis Study Findings Recently Were Reported by C. de la Cruz and Co-Researchers (Biosimilars in psoriasis: Clinical practice and regulatory...
By a News Reporter-Staff News Editor at Marketing Weekly News New research on Skin Diseases and Conditions- Psoriasis is the subject of a report. To understand the complexities of the regulatory landscape and key therapeutic issues for use of biosimilars to treat moderate to severe psoriasis in Latin America, the International Psoriasis Council c
2/17/17 - AAM Biosimilars Council Urges Supreme Court to Prioritize Access to Biosimilar Medicines
The Biosimilars Council, a division of the Association for Accessible Medicines, formerly the Generic Pharmaceutical Association, urges the Supreme Court to recognize that biosimilar medicines can generate billions of dollars in patient and health system savings- but only if patients can access them in a timely manner, as Congress directed.
2/17/17 - Amneal Introduces Alosetron Hydrochloride Tablets, New Generic for Lotronex
By a News Reporter-Staff News Editor at Drug Week- Amneal Pharmaceuticals LLC has launched alosetron hydrochloride tablets, an AB-rated generic equivalent to Lotronex , in 0.5 mg and 1 mg strengths. The Amneal product is one of only two FDA- approved generic-equivalents for Lotronex currently available. Amneal's generic received FDA approval
2/17/17 - Biocon touches fresh 52-week high, post nod by US FDA to BLA [India Infoline News Service]
US Food and Drug Administration accepted Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Neulasta, for filing through the 351 pathway. Biocon Limited touched a high of Rs 1123 per share, up by Rs 28.35 per share or 2.59% on an intraday basis in Friday's trading session, and this comes in succession to US Food and Drug
2/17/17 - Biosimilar Market: Global Industry Analysis and Opportunity Assessment, 2017 2022
Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022.. PUNE, INDIA, February 17, 2017/ EINPresswire.com/ Global Biosimilar Industry Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. However, Asia Pacif
2/17/17 - Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices - Research and Markets
By a News Reporter-Staff News Editor at Drug Week Research and Markets has announced the addition of the "Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices" report to their offering. A biosimilars boom is expected and both biopharma and contract manufacturers want to be positioned to capture a piece of the market.
2/17/17 - Blog Coverage The Biologics License Application for Mylan-Biocon's Proposed Biosimilar - Pegfilgrastim, Gets Accepted by US FDA for Review
Upcoming AWS Coverage on Mallinckrodt Post-Earnings Results. LONDON, UK/ ACCESSWIRE/ February 17, 2017/ Active Wall St. blog coverage looks at the headline from Mylan N.V as the Company and Biocon Ltd. announced on February 16, 2017 that the US Food and Drug Administration has accepted Mylan's biologics licence application for MYL-1401H a proposed.
2/17/17 - FDA to review Mylan and Biocon's biosimilar application
The US Food and Drug Administration (FDA) has accepted Mylan and Biocon's biologics license application for MYL-1401H, a proposed biosimilar to Neulasta...
2/17/17 - HEDGEPATH PHARMACEUTICALS, INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.
We are presently conducting an open label, Phase II clinical trial of proposed therapy for Gorlin Syndrome, and in August 2016 and October 2016, we announced positive interim data from this trial. We have exclusive rights in the U.S. to develop and to commercialize SUBA-Itraconazole Capsules for the treatment of human cancer via oral administration
2/17/17 - MYLAN GETS USFDA NOD FOR PROPOSED CANCER BIOSIMILAR
Mylan Inc of USA and its Indian partner, Biocon Limited of Bengaluru, have got approval from the US Food and Drug Administration for Mylan's biologics licence application for a proposed biosimilar of branded trastuzumab.
2/17/17 - New Findings from Hanyang University Hospital Yields New Data on Rheumatoid Arthritis [Efficacy and safety of CT-P13 (biosimilar infliximab) in...
By a News Reporter-Staff News Editor at Health& Medicine Week Investigators discuss new findings in Autoimmune Diseases and Conditions- Rheumatoid Arthritis. According to news originating from Seoul, South Korea, by NewsRx correspondents, research stated, "To assess the efficacy and safety of switching from the infliximab reference product to its
2/17/17 - New Psoriasis Study Findings Recently Were Reported by C. de la Cruz and Co-Researchers (Biosimilars in psoriasis: Clinical practice and regulatory...
To understand the complexities of the regulatory landscape and key therapeutic issues for use of biosimilars to treat moderate to severe psoriasis in Latin America, the International Psoriasis Council convened dermatology experts from Argentina, Brazil, Chile, Colombia and Mexico in October 2015 to review the definition, approval, marketing and fut
2/17/17 - Supply Of Generic Medicines For The Consorci Sanitari Integral Centers. [TendersInfo (India)]
Supply of generic drugs for the Consorci Sanitari Integral centers. Major organization: CONSORCI SANITARI INTEGRAL Address: C/ Jacint Verdaguer 90 08970 St. Joan Desp Country: Spain Url: http://contractaciopublica.gencat.cat Tender notice number: 58575-2017 Notice type: Tender Notice Open date: 2017-03-22.
2/17/17 - USFDA ACCEPTS BIOCON'S DRUG APPLICATION FOR REVIEW
The US Food and Drug Administration has accepted the application of Mylan Inc and Biocon Limited of Bengaluru for proposed. biosimilar pegfilgrastim, which is used for the treatment of cancer patients undergoing chemotherapy. The proposed biosimilar to Neulasta is used for reducing the duration of neutropenia.
2/17/17 - USFDA APPROVES LUPIN'S ORAL SOLUTION
The US Food and Drug Administration has given approval to Lupin Limited for the generic version of hydrocodone bitartrate and homatropine methylbromide oral solution 5 mg/1. 5 mg per 5 ML.
2/16/17 - Biosimilars Market Is Expected to Reach USD 58.40 Billion by 2022
The biosimilars market offers many growth opportunities and driving factors as compared to the restraining factors. It is stated by various research scientists that development of biosimilars will drastically reduce the price of the pharmaceutical drugs.Chicago, IL 02/16/2017 The global biosimilars market report offers in-depth analysis of th
2/16/17 - Caprion Biosciences to Present Poster at Biologic Manufacturing Asia
Caprion Biosciences Inc. announced today it has presented a poster at the 4 th Biologic Manufacturing Asia, Singapore. Laura McIntosh, Vice-President, Translation Research who added: "We will also be presenting additional results at the 3rd Annual Biologics& Biosimilar Congress in Berlin next March.. Poster presentation at the conference "High Co
2/16/17 - Generic Competitors A Looming Threat For Acorda Therapeutics Inc (NASDAQ:ACOR)
In order to ensure an extension of its Ampyra's protection to 2026, Acorda Therapeutics Inc (NASDAQ:ACOR) must fight off competition from competitors such as Roxane, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and Mylan as well as ensure it keeps its patents. This is according to Michael Yee, an RBC analyst. Ten companies have been sued
2/16/17 - Health care advocates make pitch for bills to block drug price hikes [The Baltimore Sun]
Feb. 16 Healthcare advocates who are pushing for bills to combat rising prescription drug prices in Maryland drew sympathy but also skepticism from state lawmakers Wednesday. We want them to produce generic drugs, "Attorney General Brian Frosh told the Senate Finance Committee. Leana Wen, Baltimore County Executive Kevin Kamenetz, Prince George's
2/16/17 - Lupin receives final USFDA approval for two drugs [India Infoline News Service]
The approval is for ANDA Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1. 5 mg per 5 ml, which is a generic version of Hycodan Oral Solution, 5 mg/1. 5 mg per 5 mL, manufactured by Endo Pharmaceuticals, Inc. Lupin, has announced that the Company has received USFDA approval. Lupin Limited is a transnational pharmaceutical
2/16/17 - TEVA - ANDY BOYER, GGM NORTH AMERICA PRESIDENT & CEO SPEAKS ON ASSOCIATION FOR ACCESSIBLE MEDICINES (AAM) INDUSTRY-CEO PANEL
Release date- 15022017- Today Andrew Boyer, Teva's President& CEO of Global Generic Medicines, North America spoke on a panel of industry CEOs during the annual meeting of the Association for Accessible Medicines. The AAM, formerly known as the Generic Pharmaceutical Association, hosted leadership from Teva, Momenta Pharmaceuticals, Lupin Limited a
2/16/17 - U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Feb. 16, 2017/ PRNewswire/ Mylan N.V. and Biocon Ltd. today announced that the U.S. Food and Drug Administration has accepted Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Neulasta , for filing through the 351 pathway. Arun Chandavarkar, CEO and Joint Manag
Articles(s): 1 - 25 of 153     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415